Drug Profile


Alternative Names: DAU 6215; U 98079

Latest Information Update: 22 Jul 2011

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiemetics; Benzimidazoles; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Cognition disorders; Nausea and vomiting; Psychotic disorders

Most Recent Events

  • 22 Jul 2011 Discontinued - Preclinical for Psychotic disorders in Italy (PO)
  • 22 Jul 2011 Discontinued - Phase-III for Nausea and vomiting in Europe (PO)
  • 22 Jul 2011 Discontinued - Phase-III for Nausea and vomiting in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top